Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...

Evrysdi (risdiplam, Genentech), a survival motor neuron 2 pre-mRNA splicing modifier, will be available in a 5 mg tablet that can be either swallowed whole or dissolved in water, the release said.

An infant with a fatal genetic disease has survived past the age of 2 with no signs of the condition, thanks to treatment ...

Evrysdi, marketed by Genentech, a Roche company, is a disease-modifying therapy designed to target the genetic root cause of SMA by increasing the production of the missing functional survival motor ...

Motor neurone disease (MND ... Right now, the only medication licensed in the UK is an oral tablet called riluzole. The drug has been shown, in clinical trials, to increase life expectancy ...

The new tablet, expected to be available in the coming weeks, is suitable for people two years of age or older who weigh more than 20 kgs (44 lbs). Roche leads the clinical development of Evrysdi as ...